Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.
Investment Opportunities with Five Frontline Therapies for AML
September 6, 2010 By 2 Comments
Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow. Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet. In AML, abnormal blasts produce white blood cells that do not function [...]
Buyout Buzz at ASH Hematology Confab
December 7, 2009 By 1 Comment
Scientific and medical advances weren’t the only topic of discussion at the 51st American Society of Hematology [ASH] Annual Meeting that began over the weekend in New Orleans, LA, as merger and acquisition activity took center stage. Early this morning, Celgene Corporation (CELG) announced the acquisition of privately-held Gloucester Pharmaceuticals for $340 million in cash [...]
Biotech Baker’s Dozen to Watch at Hematology Meeting
November 29, 2009 By 2 Comments
The 51st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation (CELG) recently announced that data from [...]
Follow MD Becker Partners